Open original FDA record ↗Recall record
- FDA identifier
- Z-0379-2013
- Company in FDA record
- Microgenics Corporation
- FDA classification date
- Nov 19, 2012
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 17, 2026
- Recall classification
- Class III
Reason stated in the source
In house testing confirmed that CK-MS and Insulin claimed in both Omni IMMUNE and Omni IMMUNE PRO products are displaying reduced stability.
Source facts
- Action
- Microgenics Corporation sent a Recall Notification letter dated August 20, 2012, to all affected customers. The letter identified the product the problem and the action needed to be taken by the customer. Customers were instructed that immediate attention is required and identify the two affected constituents. The letter contains a list of the affected product with their catalog number, lot number and expiration date and request that the CK-MB and Insulin use be discontinued. The remaining components of the product may be used. Evaluate quality controls according to your laboratory procedures. Retain a copy of the letter for your laboratory records. If the product was forwarded to another laboratory, provide them with a copy of the letter. Complete the attached Recall Response form and return within 5 days. Questions may be directed to 1-800-232-3342.
- Initiated
- 2012-08-20
- Root cause
- Nonconforming Material/Component
- Terminated
- 2013-03-04
- Distribution
- Worldwide Distribution--USA (nationwide) and the countries of Germany, Canada and Australia.
- Recall number
- Z-0379-2013
- Recall status
- Terminated
- CDRH record ID
- 112207
- FDA classified
- 2012-11-19
- Recall event number
- 62987